FOLR2 and neoplasm: While the nature of the change in FRβ from nonfunctional to functional state could not be ascertained by sensitive mass spectrometry analyses (data not shown), the selective activation of FRβ+ in tumor tissues enables targeting of drugs to myeloid cells in solid tumors without perturbing their properties in healthy tissues.